Zacks Investment Research upgraded shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.
According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Other equities analysts have also recently issued reports about the company. Needham & Company LLC reiterated a buy rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. Piper Jaffray Companies reiterated an overweight rating and issued a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Wednesday. ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 1st. Mizuho reiterated a buy rating and issued a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. Finally, BidaskClub cut Adamas Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $36.67.
Adamas Pharmaceuticals (NASDAQ ADMS) traded down 0.19% during trading on Thursday, reaching $21.28. The company’s stock had a trading volume of 266,941 shares. The company’s market cap is $479.10 million. The stock has a 50-day moving average price of $18.21 and a 200 day moving average price of $17.22. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $23.84.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the previous year, the firm earned ($0.78) earnings per share. Adamas Pharmaceuticals’s quarterly revenue was down 90.9% compared to the same quarter last year. On average, analysts expect that Adamas Pharmaceuticals will post ($3.77) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Upgraded to “Hold” at Zacks Investment Research” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://sportsperspectives.com/2017/09/22/adamas-pharmaceuticals-inc-adms-upgraded-to-hold-at-zacks-investment-research.html.
Several institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. boosted its holdings in shares of Adamas Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 682 shares in the last quarter. Alps Advisors Inc. boosted its holdings in shares of Adamas Pharmaceuticals by 6.7% in the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after purchasing an additional 1,272 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Adamas Pharmaceuticals by 2.4% in the 1st quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after purchasing an additional 1,563 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Adamas Pharmaceuticals by 28.4% in the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 3,358 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Adamas Pharmaceuticals by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after acquiring an additional 5,920 shares during the last quarter. Hedge funds and other institutional investors own 69.24% of the company’s stock.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.